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A B S T R A C T
We present a case of Rhodococcus equi primary retroperitoneal abscesses without pulmonary
involvement in an immunocompromised patient with severe nephrotic syndrome. No risk factors for
exposure to R. equi were present. The infection was successfully treated with long-term combination
antibiotic treatment including linezolid and tigecycline.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Rhodococcus equi is a facultative, intracellular, Gram-positive
coccobacillus which primarily causes pyogranulomatous bronch-
opneumonia in foals.1 Over the last few years, R. equi has emerged
as a human opportunistic pathogen in immunocompromised
patients, especially those with AIDS.2–4 With the introduction of
potent antiretroviral therapy, cases related to HIV immunodeﬁ-
ciency have decreased. However R. equi infections are increasingly
reported in transplant recipients and in patients receiving
immunosuppressive and/or prolonged corticosteroid treat-
ment.5–7
The ﬁrst site of infection is commonly the lung, and it results in
a necrotizing pneumonia (80% of cases), which clinically resembles
mycobacterial, fungal or nocardial pulmonary infections.2 Primary
extrapulmonarymanifestations are unusual andmainly secondary
to hematogenous dissemination from a silent lung infection. We
describe herein a case of R. equi primary retroperitoneal abscesses
with no evidence of either pulmonary involvement or hemato-* Corresponding author. Tel.: +39 (0)6 49970313; fax: +39 (0)6 49972625.
E-mail address: gianluca.russo@uniroma1.it (G. Russo).
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severe nephrotic syndrome. The infection was successfully treated
with long-term combination antibiotic treatment including line-
zolid and tigecycline.
2. Case report
A 44-year-old man with nephrotic syndrome and focal-
segmental glomerulosclerosis treated with brief cycles of cyclos-
porine and long-term dexamethasone for 6 years, presented with a
2-week history of severe lumbar pain involving the left leg. On
admission, he was afebrile and was unable to walk or maintain a
standing position. He underwent magnetic resonance imaging
(MRI),which showedavoluminousﬂuidmass (18  8 cm) in the left
psoas muscle. A chest X-raywas normal and a total body computed
tomography (CT) scan revealed no disease localization in lung or
other extrapulmonary sites. Laboratory tests showed leukocytosis
(white blood cell count 27.3  109 cells/l, 98% of neutrophils), high
inﬂammatory index (C-reactive protein (CRP) 25.7 mg/dl), serum
creatinine of 1.6 mg/dl, proteinuria (22.5 g/24 h), decreased crea-
tinine clearance (59.3 ml/min), and serum albumin of 1.6 g/dl. A
surgical drainage of the abscess was done and bacterioscopic
examination showed partially acid-fast coccobacilli consistent withses. Published by Elsevier Ltd. All rights reserved.
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nem and tetracycline was started. Serology for HIV infection was
negative, however lymphopenia (<0.5  109 cells/l) associatedwith
low levels of both CD4+ T-cells (<0.2  109 cells/l) and low total
circulating IgG (204 mg/dl) was found. After a week of treatment, a
controlMRI showedanewvoluminousﬂuidmass (10  8 cm) in the
medial region of the right thigh and another involving the
homolateral gastrocnemius muscle. Two new drainage catheters
were placed. After 48 h the drainage ﬂuid culture grew Rhodococcus
spp, identiﬁed by Gram stain reaction, microscopic and colony
morphology, growthcharacteristics, andasynergistichemolysis test
using Corynebacterium pseudotuberculosis.8 The biochemical proﬁle
of the isolatewas deﬁned using the API Coryne System (BioMerieux,
Marcy l’Etoile, France) conﬁrming the strain identiﬁcation as R. equi.
Antibiotic susceptibility testing was performed through broth
microdilution, E-test strips, and disk diffusion, as previously
reported.9,10 No risk factors for environmental exposure to R. equi
were identiﬁed.
The R. equi strain was resistant to erythromycin (minimum
inhibitory concentration (MIC)>6mg/ml), rifampin (MIC>128mg/
ml), and tetracycline (MIC >16mg/ml). Antibiotic therapy was
changed to intravenous levoﬂoxacin (MIC = 0.25mg/ml), vancomy-
cin (MIC = 4mg/ml), and imipenem (MIC< 1mg/ml), with dose
adjustment for creatinine clearance. Laboratory tests showed
persistence of neutrophil leukocytosis, lymphopenia, and a severe
circulating IgG deﬁcit. After 4 weeks of treatment there was no
signiﬁcant reduction of the abscesses. The inﬂammation index
decreased (CRP 2.5 mg/dl), but renal function was worsening. In
order to improve treatment efﬁcacy and reduce the nephrotoxicity
risk of antimicrobial therapy, we tested the susceptibility of the
isolatedR. equi to linezolid (MIC = 1mg/ml)9 and tigecycline (23 mm
inhibition diameter using agar disk diffusionmethod corresponding
to a MIC of <2mg/ml).11 Considering the lack of nephrotoxicity of
these two antibiotics and their in vitro activity, treatment was then
switched to intravenous linezolid and tigecycline. A marked
reduction of ﬂuidmass was seenwithout any impairment of kidney
function. Two weeks later, the patient was discharged with oral
linezolid. Under this treatment his clinical condition improved,
neutrophil leukocytosis decreased, and a drainage catheter wasFigure 1. Computed tomography scan of Rhodococcus equi retroperitoneal psoas abscess
muscle; C: control scan showing complete resolution after successful treatment.removed. After one month, the patient was again hospitalized
because of the onset of generalized seizures; a brain MRI revealed
lesions compatible with cerebritis. A new culture of drainage ﬂuid
from a retroperitoneal site grew Serratia marcescens, but R. equiwas
not isolated. Antibiotic therapy was changed to intravenous
linezolid and meropenem, which were administered for a total of
12 weeks. The clinical and laboratory parameters improved. All
microbiological cultures from blood and drainage catheters were
sterile. AbrainMRI showeddisappearanceof the cerebritic lesions. A
control CT scan revealed that all abscesses had almost disappeared,
and the remaining drainage catheters were removed (Figure 1). The
patient did not at any time suspend the steroid treatment for his
nephrotic syndrome. In order to prevent a relapse of the R. equi
infection, secondary antibiotic prophylaxis with moxiﬂoxacin (MIC
<0.25mg/ml) was administered for 4 months; this was interrupted
when the patient stopped steroid treatment and underwent
hemodialysis because of the worsening of his renal disease. After
6 months of regular hemodialysis the immunologic condition had
improved and a control CT scan showed no relapse of infection.
3. Discussion
R. equi has become increasingly recognized as a cause of severe
infections in immunocompromised patients without HIV dis-
ease.5–7 The infection mortality rate is still high (20–25%)12 and
disease relapses are common.13 A wide range of clinical
manifestations have been reported, although pneumonia is present
in about 80% of R. equi infections.2 Our case represents a primary
extrapulmonary manifestation of R. equi infection presenting as
retroperitoneal abscesses, with no evidence of pulmonary involve-
ment or hematogenous dissemination. It is interesting to note that
there were no environmental exposures that may have predis-
posed this patient to acquiring R. equi. Bacterial virulence factors
and host immunity play an important role in the pathogenesis of R.
equi infections. The presence of the well-known virulence-
associated antigens was not found to be essential for the
development of R. equi infection in humans.14 On the other hand,
both cellular and humoral immunity play a crucial role in the host
response against R. equi.15,16 In the present patient, the main: A and B: pre-therapy scan showing ﬂuid mass (18  10 cm) in the left psoas major
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nephrotic syndrome treated with prolonged steroid therapy. He
had an immunoglobulin deﬁcit due to persistent proteinuria (22–
30 g/24 h) and also a severe lymphopenia, which might have
contributed to the development of the disease.
Surgical drainage and antibiotic therapyare the gold standard for
the management of retroperitoneal abscesses. There is no standar-
dized antibiotic treatment for R. equi infection. R. equi is usually
susceptible in vitro to macrolides, rifampin, aminoglycosides,
ﬂuoroquinolones, glycopeptides, and carbapenems; susceptibility
to co-trimoxazole, tetracycline, clindamycin, chloramphenicol, and
cephalosporins is variable.2 It is suggested that more serious
infections should initially be treated intravenously using a
combination of two or three drugs, such as vancomycin, imipenem,
rifampin, quinolones, and macrolides.2,12,17 A long-term mainte-
nance treatment with antibiotics having good intracellular pene-
tration (i.e., macrolides plus rifampin or quinolones) is required in
order to fully eradicate the infection and prevent disease relapses. A
secondary prophylaxis with a single agent that has in vitro activity
should be strongly considered for patients with ongoing immuno-
suppression.2
Antibiotic susceptibility testing was performed in our case
through broth microdilution, E-test strips and disk diffusion: all
methods were comparable, with good reproducibility. The E-test is
a simple method, which does not require special equipment,
allowing the measurement of MIC values. Moreover the inter-
pretation ofMIC categories by E-testmethod highly correlateswith
those of either microdilution or disk-diffusion when testing
coryneform bacteria.18 Antimicrobial susceptibility testing of R.
equi remains problematic because the criteria for deﬁning the
susceptibility breakpoints of the different antibiotics are still
controversial. Our data in the present study are based on the
standards reported by other authors in the literature.9,10,19 The R.
equi strain of our patient was resistant tomacrolides, rifampin, and
tetracycline, but susceptible to quinolones, vancomycin, and
carbapenems. Although this sensitivity pattern is unusual, it
was seen in a case series of invasive R. equi infections showing
emergence of multidrug-resistant strains.20 The resistance pattern
of our strain, which involved three antibiotic classes with
intracellular activity, should be taken into account in the selection
of a therapeutic regimen for rhodococcal infections. After a 4-week
treatment with imipenem, levoﬂoxacin, and vancomycin we did
not observe signiﬁcant clinical improvement. All the antibiotics
used had a high renal excretion and required dose adjustment,
possibly resulting in sub-therapeutic plasma concentrations. The
antibiotic plasma protein binding (PPB) was another crucial issue
in our case, because of a persistent and irreversible serum albumin
deﬁcit that could have affected drug pharmacokinetics. On the
basis of these considerations, we decided to modify the antibiotic
treatment, switching to linezolid and tigecycline. Little is known
about the efﬁcacy of these two antibiotics in the treatment of R.
equi infections. Linezolid has some in vitro activity9 and a
successful treatment of R. equi pneumonia in a heart transplant
recipient has been described.21 Tigecycline has been reported to
show good in vitro activity against R. equi,22 but clinical experience
is still lacking. In our case, the combination of linezolid and
tigecycline induced a rapid clinical improvement and reduction of
retroperitoneal abscesses. Tigecycline was used for 14 days, while
linezolid was administered for a total of 18 weeks without any
impact on kidney function. Considering the patient’s immune
system impairment due to the severity of his nephrotic syndrome,a secondary prophylaxis withmoxiﬂoxacin was administered until
steroid therapy was stopped and a regular hemodialysis treatment
was started.
In conclusion our case indicates the increasing clinical
relevance of R. equi as a cause of extrapulmonary manifestations
in immunocompromised patients. The combination of tigecycline
and linezolid may represent a reasonable therapeutic alternative
for R. equi infections, especially in selected patients with severe co-
morbidities.
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